Role of riboflavin- and UV light-treated plasma in prevention of transfusion-related acute lung injury

Transfusion Medicine and Hemotherapy

Volumn 41, Issue 3, 2014, Pages 172-175

  Jimenez Marco, Teresa ^a,b   Ruiz Alderton, Daniel ^a   Bautista Gili, Antonia M ^a   Girona Llobera, Enrique ^a,b  

^a Fundació Banc de Sang i Teixits de les Illes Balears ^*  (Spain)

^b RediAPP   (Spain)

Author keywords

Plasma; Riboflavin; TRALI; UV light

Indexed keywords

FRESH FROZEN PLASMA; RIBOFLAVIN;

ANALYTIC METHOD; ARTICLE; BLOOD DONOR; BLOOD SAFETY; FEMALE; HUMAN; MALE; TRANSFUSION RELATED ACUTE LUNG INJURY; ULTRAVIOLET RADIATION; BLOOD GROUP AB; BLOOD GROUP B; DRUG USE; ERYTHROCYTE TRANSFUSION; INCIDENCE; MAJOR CLINICAL STUDY; SEX DIFFERENCE;

EID: 84902469297     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000363205     Document Type: Article

References (21)

1. Goodrich RP, Doane S, Reddy HL: Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010;38: 20-30.
2. Goodrich RP, Li J, Edrich R, Seghatchian J: The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35: 5-17.
3. Petteys BJ, Frank EL: Rapid determination of vitamin B2 (riboflavin) in plasma by HPLC. Clin Chim Acta 2011;412: 38-43.
4. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP: Toxicity testing of a novel riboflavin- based technology for pathogen reduction and white blood activation. Transfus Med Rev 2008;22: 133-153.
5. European Directorate for the Quality of Medicines and Health Care: Guide for the Preparation, Use and Quality Assurance of Blood Components, 17th ed. Strasbourg, Council of Europe, 2013.
6. Alvarez-Larrán A, Del Río J, Ramírez C, Albo C, Peña F, Campos A, Cid J, Muncunill J, Sastre J-L, Sanz C, Pereira A: Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86: 246-251.
7. Río-Garma J, Alvarez-Larrán A, Martínez C, Muncunill J, Castellà D, de la Rubia J, Zamora C, Corral M, Viejo A, Peña F, Rodríguez-Vicente P, Contrears E, Arbona C, Ramírez C, Garcia-Arce J A, Alegre A, Mateo J, Pereira A: Methylene blue-photoinactivated plasma vs. fresh-frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008;143: 39-45.
8. Commission Directive 2005/61/EC of 30 September 2005 Implementing Directive 2002/98/EC of the European Parliament and of the Council as regards Traceability Requirements and Notification of Serious Adverse Reactions and Events. http://eur-lex.europa. eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:2 56:0032:0040:EN:PDF (last accessed April 29, 2014).
9. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA: Proceedings of a Consensus Conference: pathogen inactivationmaking decisions about new technologies. Transfus Med Rev 2008;22: 1-34.
10. Seltsam A, Müller TH: Update on the use of pathogen- reduce human plasma and platelet concentrates. Br J Haematol 2013;162: 442-454.
11. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM 3rd: Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transfusion 2007;84: 1174-1182.
12. Marschner S, Fast LD, Baldwin WM 3rd, Slichter SJ, Goodrich RP: White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010;50: 2489-2498.
13. Fast LD, Nevola M, Tavares J, Reddy HL, Goodrich RP, Marschner S: Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion- associated graft-versus-host disease? Transfusion 2013;53: 373-381.
14. Palfi M, Berg S, Ernerudh J, Berlin G: A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion 2001;41: 317-322.
15. Wallis JP, Lubenko A, Wells AW: Chapman CE: Single hospital experience of TRALI. Transfusion 2003;43: 1053-1059.
16. Bolton-Maggs PHB, Cohen H: Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013;163: 303-314.
17. Silliman CC, Khan SY, Bradley Ball J, Kelher MR, Marschener S: Mirasol Pathogen Reduction Technology ® treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components. Vox Sang 2010;98: 525-530.
18. Smith J, Rock G: Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010;50: 926-931.
19. Jimenez-Marco T, Girona-Llobera E, de Fuertes A, Quetglas B, Acosta R, Sedeño M: Riboflavin and UV-light treated plasma in vitro quality evaluation. Vox Sang 2013;105(suppl 1):155.
20. Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ. Maldonado-Codina G, Goodrich RP: Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18 °C. Transfus Apher Sci 2012;46: 15-18.
21. Letowska M, Windyga J, Poglod R, Rosiek A, Rzymkiewicz L, Bykowska K, Lachert E: Mirasol clinical effect of therapeutic plasma exchange (TPE) with Mirasol PRT-treated fresh frozen plasma in patients with acquired thrombotic thrombocytopenic purpura (TTP). Transfusion 2013;53(suppl):116A.